Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study
Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study
早前报道，传奇生物CARVYKTI在三期CARTITUDE-4研究中显示出改善的微小残留病阴性率和总体生存益处。
- 89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 months
- Results add to the overall survival (OS) benefit recently reported making CARVYKTI the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma
- Landmark Phase 3 CARTITUDE-4 study data featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
- 在CARTITUDE-4研究中，经过三年跟踪，89%的可评估患者在使用CARVYKTI后达到了微小残留病（MRD）阴性；大多数患者在不到2个月内达成这一结果。
- 结果补充了最近报告的总体生存（OS）益处，证明CARVYKTI是首个也是唯一一个在多发性骨髓瘤中相比标准疗法显著延长OS的电芯疗法。
- 作为口头报告，CARTITUDE-4的里程碑III期研究数据在第66届美国血液学会（ASH）年会和博览会上进行了展示。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间